Uptake Medical Names J.C. MacRae as Chief Financial Officer
Published: Nov 16, 2010
MacRae comes to Uptake Medical with over 25 years experience in the medical specialty device and biopharmaceutical product industries. He most recently was a member of the senior management team at CoreValve, Inc., a catheter-based heart valve replacement company, recently acquired by Medtronic (MDT-NYSE), serving as chief financial officer and managing director of CoreValve Europe, BV. During his career to date, MacRae has held senior general and financial management positions with innovative medical product companies and has led three successful IPOs and numerous private financings, and has a broad range of experience that includes initial product launches worldwide, business development, product licensing, and mergers and acquisitions. MacRae graduated from University of California, Irvine and has a MBA from California State University, Fullerton.
Uptake Medical is developing the InterVapor System, a minimally invasive method of treating emphysematous lung tissue. InterVapor delivers thermal vapor to the diseased areas, reducing the lung volume, expanding breathing capacity and improving overall breathing mechanics. The InterVapor System employs a bronchoscopic vapor delivery catheter and vapor generator plus an individualized patient procedure program called IP3 that customizes the treatment to each patient's physiology and condition.
"We are excited to have J.C. join Uptake Medical with his extensive global financial and medical device industry experience. His direct experience and leadership in assisting medical technology companies achieve growth and profitability will be directly applicable to Uptake's near term plans including global expansion, manufacturing scale-up, international distribution and fundraising," noted King Nelson, president and chief executive officer of Uptake Medical.
About Uptake Medical
Uptake Medical Corp. is a developer of proprietary medical technologies for the treatment of lung diseases including emphysema. The company's core technology is InterVapor, a simple, minimally invasive, non-implantable interventional pulmonary therapy designed to measurably improve lung function and patient quality of life. More information and a list of participating clinical trial sites can be found at http://www.uptakemedical.com/.
SOURCE Uptake Medical Corp.